Clocking cancer: the circadian clock as a target in cancer therapy

Area of Science:

• Chronobiology
• Oncology
• Molecular Biology

Background:

• The circadian clock, a cellular pathway regulating 24-h rhythms via transcription-translation feedback loops, is increasingly implicated in cancer.
• Dysregulation of core circadian clock genes is common in human tumors, but mechanisms vary by cancer type and are not fully understood.
• Specific oncogenes can differentially disrupt the circadian clock in tumor development.

Purpose of the Study:

• To provide an overview of the rationale and current evidence for targeting the circadian clock in cancer treatment.
• To highlight the potential of modulating clock components as a novel anti-cancer therapeutic strategy.

Main Methods:

• Review of existing literature on circadian clock function in cancer.
• Analysis of studies investigating the effects of circadian clock gene dysregulation in various cancer types.
• Examination of preclinical and clinical evidence for targeting the circadian clock in cancer therapy.

Main Results:

• Circadian clock disruption is associated with cancer risk, development, and progression.
• Expression of core circadian clock genes is frequently altered in human tumors.
• Pharmacological targeting of clock components demonstrates cancer-specific cell lethality.

Conclusions:

• Targeting the circadian clock represents a promising novel therapeutic approach for cancer treatment.
• Further research is needed to fully elucidate the mechanisms underlying clock dysregulation in different cancer types.
• Exploiting the interplay between oncogenes and the circadian clock may lead to more effective cancer therapies.